St. Jude’s Flexible Pacer Receives CE Mark

St. Jude's Flexible Pacer Receives CE MarkSt. Paul, MN – June 26, 2013 – St. Jude Medical landed CE Mark approval for its Quadra Assura MP. The Qudar Assura MP can be used to pace multiple locations on the left side of a patient’s heart. The device is able to increase the number of cardiac patients who are responsive to therapy.

Paired with the Quartet lead, the Quadra Assura MP includes four customized electrodes. These electrodes deliver charges at intervals and locations determined by a physician. Through the company’s MultiPoint Pacing system, the device has increased the number of patients who can benefit from cardiac resynchronization therapy.

In a trial of the device, 89% of heart failure patients responded to treatment with the Quandra Assura MP. This represents a 20% increase over traditional CRT technologies.

As the company plans to commercialize the device in Europe, the company is recruiting 500 qualified patients at test centers in the United States. Armed with upcoming data from a U.S.-based trial, the company hopes to land FDA approval.

“We are pleased to continue our innovation by offering the industry’s first MultiPoint Pacing system, which provides a new set of non-invasive tools to address patients who are non-responders to traditional CRT pacing, potentially decreasing heart failure hospitalizations and lowering the economic burden,” stated Eric Fain, president of Implantable Electronics Systems DIvision at St. Jude Medical.St. Jude Medical landed CE Mark approval for its Quadra Assura MP. The Qudar Assura MP can be used to pace multiple locations on the left side of a patient’s heart. The device is able to increase the number of cardiac patients who are responsive to therapy.

Paired with the Quartet lead, the Quadra Assura MP includes four customized electrodes. These electrodes deliver charges at intervals and locations determined by a physician. Through the company’s MultiPoint Pacing system, the device has increased the number of patients who can benefit from cardiac resynchronization therapy.

In a trial of the device, 89% of heart failure patients responded to treatment with the Quandra Assura MP. This represents a 20% increase over traditional CRT technologies.

As the company plans to commercialize the device in Europe, the company is recruiting 500 qualified patients at test centers in the United States. Armed with upcoming data from a U.S.-based trial, the company hopes to land FDA approval.

“We are pleased to continue our innovation by offering the industry’s first MultiPoint Pacing system, which provides a new set of non-invasive tools to address patients who are non-responders to traditional CRT pacing, potentially decreasing heart failure hospitalizations and lowering the economic burden,” stated Eric Fain, president of Implantable Electronics Systems DIvision at St. Jude Medical.
Media Contact:
Qmed
UBM Canon
2901 28th St., Ste. 100
Santa Monica, CA 90405
Tel: 310/445-4200
Fax: 310/445-4299
Click to visit website

Advertisements

About Ember Branch
Ember Branch is all about health and lifestyle committed to publishing articles related to natural health, health care, diet and nutritions, medical technology, wellness and fitness, family health, and reviews and at the same time encourages the readers to participate in open dialogues, discussions, and comments.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: